Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.730
+0.010 (0.58%)
At close: Feb 21, 2025, 4:00 PM
1.700
-0.030 (-1.73%)
After-hours: Feb 21, 2025, 7:59 PM EST
Heron Therapeutics Market Cap
Heron Therapeutics has a market cap or net worth of $263.12 million as of February 21, 2025. Its market cap has decreased by -21.39% in one year.
Market Cap
263.12M
Enterprise Value
370.48M
1-Year Change
-21.39%
Ranking
Category
Stock Price
$1.73
Market Cap Chart
Since December 1, 1998, Heron Therapeutics's market cap has increased from $127.40M to $263.12M, an increase of 106.53%. That is a compound annual growth rate of 2.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 20, 2025 | 261.60M | 12.42% |
| Dec 31, 2024 | 232.70M | -8.78% |
| Dec 29, 2023 | 255.10M | -14.17% |
| Dec 30, 2022 | 297.20M | -68.07% |
| Dec 31, 2021 | 930.70M | -51.60% |
| Dec 31, 2020 | 1.92B | -9.13% |
| Dec 31, 2019 | 2.12B | 4.57% |
| Dec 31, 2018 | 2.02B | 105.15% |
| Dec 29, 2017 | 986.50M | 92.15% |
| Dec 30, 2016 | 513.40M | -46.54% |
| Dec 31, 2015 | 960.40M | 227.11% |
| Dec 31, 2014 | 293.60M | 110.32% |
| Dec 31, 2013 | 139.60M | -15.24% |
| Dec 31, 2012 | 164.70M | 258.04% |
| Dec 30, 2011 | 46.00M | 154.14% |
| Dec 31, 2010 | 18.10M | -63.51% |
| Dec 31, 2009 | 49.60M | 281.54% |
| Dec 31, 2008 | 13.00M | -73.25% |
| Dec 31, 2007 | 48.60M | 39.66% |
| Dec 29, 2006 | 34.80M | -10.08% |
| Dec 30, 2005 | 38.70M | -6.30% |
| Dec 31, 2004 | 41.30M | -18.22% |
| Dec 31, 2003 | 50.50M | 146.34% |
| Dec 31, 2002 | 20.50M | -63.91% |
| Dec 31, 2001 | 56.80M | 18.33% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 784.71B |
| UnitedHealth Group | 429.24B |
| Novo Nordisk | 391.83B |
| Johnson & Johnson | 390.76B |
| AbbVie | 356.74B |
| Abbott Laboratories | 234.01B |
| AstraZeneca | 229.50B |
| Merck & Co. | 226.40B |